Danaher had a disappointing 2024. The trail to success subsequent yr lies on Wall Road

A worker uses a Pall Corp. manufactured machine during a demonstration of the clearance phase of flu vaccine production during a tour of a Sanofi Pasteur vaccine production facility in Swiftwater, Pennsylvania.

Stephen Hilger | Bloomberg | Getty Images

Life sciences company Danaher certainly wasn't an easy stock to buy this year. A wave of startups going public on Wall Street would go a long way toward changing that.

Comments are closed.